382 related articles for article (PubMed ID: 17594730)
1. Mucolytics, expectorants, and mucokinetic medications.
Rubin BK
Respir Care; 2007 Jul; 52(7):859-65. PubMed ID: 17594730
[TBL] [Abstract][Full Text] [Related]
2. The pharmacologic approach to airway clearance: mucoactive agents.
Rubin BK
Respir Care; 2002 Jul; 47(7):818-22. PubMed ID: 12088552
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the efficacy of mucoactive aerosol therapy.
Fuloria M; Rubin BK
Respir Care; 2000 Jul; 45(7):868-73. PubMed ID: 10926385
[TBL] [Abstract][Full Text] [Related]
4. Mucoactive agents for airway mucus hypersecretory diseases.
Rogers DF
Respir Care; 2007 Sep; 52(9):1176-93; discussion 1193-7. PubMed ID: 17716385
[TBL] [Abstract][Full Text] [Related]
5. Mucolytics in cystic fibrosis.
Henke MO; Ratjen F
Paediatr Respir Rev; 2007 Mar; 8(1):24-9. PubMed ID: 17419975
[TBL] [Abstract][Full Text] [Related]
6. Mucus structure and properties in cystic fibrosis.
Rubin BK
Paediatr Respir Rev; 2007 Mar; 8(1):4-7. PubMed ID: 17419972
[TBL] [Abstract][Full Text] [Related]
7. Other medications for aerosol delivery.
Rubin BK
Paediatr Respir Rev; 2006; 7 Suppl 1():S76-9. PubMed ID: 16798603
[TBL] [Abstract][Full Text] [Related]
8. Aerosol Medications for Treatment of Mucus Clearance Disorders.
Rubin BK
Respir Care; 2015 Jun; 60(6):825-9; discussion 830-32. PubMed ID: 26070577
[TBL] [Abstract][Full Text] [Related]
9. Physiology of airway mucus clearance.
Rubin BK
Respir Care; 2002 Jul; 47(7):761-8. PubMed ID: 12088546
[TBL] [Abstract][Full Text] [Related]
10. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics.
Broughton-Head VJ; Smith JR; Shur J; Shute JK
Pulm Pharmacol Ther; 2007; 20(6):708-17. PubMed ID: 17055310
[TBL] [Abstract][Full Text] [Related]
11. Mucus and mucins.
Rubin BK
Otolaryngol Clin North Am; 2010 Feb; 43(1):27-34, vii-viii. PubMed ID: 20172254
[TBL] [Abstract][Full Text] [Related]
12. The pharmacologic approach to airway clearance: mucoactive agents.
Rubin BK
Paediatr Respir Rev; 2006; 7 Suppl 1():S215-9. PubMed ID: 16798570
[TBL] [Abstract][Full Text] [Related]
13. Other mucoactive agents for cystic fibrosis.
Bye PT; Elkins MR
Paediatr Respir Rev; 2007 Mar; 8(1):30-9. PubMed ID: 17419976
[TBL] [Abstract][Full Text] [Related]
14. Physical and functional properties of airway secretions in cystic fibrosis--therapeutic approaches.
Puchelle E; de Bentzmann S; Zahm JM
Respiration; 1995; 62 Suppl 1():2-12. PubMed ID: 7792436
[TBL] [Abstract][Full Text] [Related]
15. Mucus-controlling agents: past and present.
King M; Rubin BK
Respir Care Clin N Am; 1999 Dec; 5(4):575-94. PubMed ID: 10565882
[TBL] [Abstract][Full Text] [Related]
16. Inhaled interventions in cystic fibrosis: mucoactive and antibiotic therapies.
Hurt K; Bilton D
Respiration; 2014; 88(6):441-8. PubMed ID: 25472021
[TBL] [Abstract][Full Text] [Related]
17. [Mucolytics in acute and chronic respiratory tract disorders. I. Pathophysiology and mechanisms of action].
Kupczyk M; Kuna P
Pol Merkur Lekarski; 2002 Mar; 12(69):245-7. PubMed ID: 12053600
[TBL] [Abstract][Full Text] [Related]
18. [Novel approach to respiratory pharmacology--pharmacological basis of cough, sputum and airway clearance].
Miyata T
Yakugaku Zasshi; 2003 Dec; 123(12):987-1006. PubMed ID: 14689863
[TBL] [Abstract][Full Text] [Related]
19. Mucoactive drugs.
Balsamo R; Lanata L; Egan CG
Eur Respir Rev; 2010 Jun; 19(116):127-33. PubMed ID: 20956181
[TBL] [Abstract][Full Text] [Related]
20. The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin beta 4.
Kater A; Henke MO; Rubin BK
Ann N Y Acad Sci; 2007 Sep; 1112():140-53. PubMed ID: 17496063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
